On Thursday, JMP Securities analyst Silvan Tuerkcan updated the investment firm’s outlook on Taysha Gene Therapies (NASDAQ: TSHA), increasing the price target from $5.00 to $6.00 while maintaining a ...

On Thursday, JMP Securities analyst Silvan Tuerkcan updated the investment firm’s outlook on Taysha Gene Therapies (NASDAQ: TSHA), increasing the price target from $5.00 to $6.00 while ...

Taysha Gene Therapies announced a public offering of shares priced at $2.75 each, aiming for $200 million in gross proceeds. Taysha Gene Therapies successfully priced a public offering of ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has announced pivotal progress in its TSHA-102 gene therapy program for Rett syndrome, following written alignment with the FDA on a single-arm, open ...

DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus ...

DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV ...

The latest price target for Taysha Gene Therapies (NASDAQ:TSHA) was reported by Canaccord Genuity on June 3, 2025. The analyst firm set a price target for $11.00 expecting TSHA to rise to within ...

NEW YORK – Taysha Gene Therapies on Wednesday said it has reached alignment with the US Food and Drug Administration for an upcoming pivotal trial of TSHA-102, a gene therapy the company is developing ...